Clinical trial NCT06970756: A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
Official title: A Phase I, Randomized, Double-blind, Parallel-controlled Clinical Study to Evaluate the Safety of a 26-valent Pneumococcal Conjugate Vaccine in Individuals Aged 60 and Above
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Pneumococcal Diseases
Keywords: 26-valent Pneumococcal Conjugate Vaccine
Lead sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2025-05-14
Enrollment: 60
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This Phase I, randomized, double-blind, parallel-controlled study is to be conducted in healthy adults aged 60 and above. Participants will be randomly assigned in a 1:1 ratio to receive either 26-valent Pneumococcal Conjugate Vaccine (PCV26) or the comparator (PCV13) on Day 1 (Visit 1). Solicited adverse events (AEs) will be collected for 7 days post-vaccination and unsolicited AEs for 28 days post-vaccination, with safety data limited to serious adverse events (SAEs), and newly diagnosed chronic medical conditions (NDCMCs) collected up to 6 months post-vaccination.


Eligibility criteria: Inclusion Criteria:

* Aged 60 years or older at the time of enrollment.
* Evidence of a personally signed and dated ICF indicating that the participant has been informed of all pertinent aspects of the study.
* Able to comply with the protocol, and capable of using a thermometer, a ruler, and fill out the diary card and contact card as required.
* Negative pregnancy test (urine) for female participants of childbearing potential. Male and non-pregnant, non-lactating females must also meet one of the following criteria: a). Female participant of nonchildbearing potential; male participant not able to father children; b). Agrees to consistently practice contraception until at least 28 days after vaccination by one of the following methods: condoms, male or female, with or without spermicide; diaphragm or cervical cap with spermicide; intrauterine device; contraceptive pills or patch; Norplant, Depo-Provera, or other FDA approved contraceptive method; or a female participant with a male partner who has previously undergone a vasectomy.

Exclusion Criteria:

* Current febrile illness (oral temperature ≥100.4°F \[≥38.0°C\]) within 48 hours before vaccine administration.
* History of an infectious disease caused by Streptococcus pneumoniae confirmed by any modality of diagnosis within the last 3 years.
* History of any pneumococcal vaccination within the last 3 years.
* History of severe allergic reactions to any drug or vaccine, especially to any component of pneumococcal vaccines (including Pneumovax, any other tetanus toxoid-containing vaccine, or 13-valent pneumococcal conjugate vaccine), such as respiratory distress, angioedema, anaphylactic shock, allergic purpura, or thrombocytopenic purpura.
* History of any serious chronic disorder including respiratory diseases (eg., severe chronic obstructive pulmonary disease requiring supplemental oxygen, severe asthma), chronic hepatitis, chronic kidney disease (eg., end-stage renal disease with or without dialysis), clinically unstable cardiac diseases or cardiovascular diseases (eg., untreated or resistant hypertension \[repeated office SBP \>150 mmHg and/or DBP \>95 mmHg\], chronic cardiac insufficiency, coronary atherosclerotic heart disease), or clinically significant forms of drug or alcohol abuse or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
* Participants with known or suspected immunodeficiency or other conditions associated with immunosuppression, including, but not limited to, immunoglobulin class/subclass deficiencies, generalized malignancy, human immunodeficiency virus (HIV) infection, leukemia, lymphoma, or organ or bone marrow transplant.
* History of thrombocytopenia, any coagulation disorder, receiving anticoagulant therapy, or any condition contraindicating administration of intramuscular injections.
* History of asplenia, splenectomy, or functional asplenia for any reason.
* Participants who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, or planned receipt within 28 days of vaccination. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before vaccination. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
* Participants who has an acute illness or exacerbation of chronic illness ≤3 days before enrollment, or use of antipyretics, analgesics, and antihistamines (eg, acetaminophen, ibuprofen, aspirin) within this timeframe.
* Participants who have received any non-live vaccine ≤7 days before receipt of study vaccine; is scheduled to receive any non-live vaccine within 7 days (≤7 days) following receipt of the study vaccine; has received any live vaccine ≤14 days before receipt of the study vaccine; or is scheduled to receive any live vaccine within 7 days (≤7 days) following receipt of the study vaccine.
* Participation in other studies involving study drug(s), study vaccines, or study devices within 28 days prior to study enrollment and/or during study participation. Participation in purely observational studies is acceptable.
* Any ≥ Grade 2 laboratory abnormality or any lab abnormality that, in the opinion of the investigator, renders the participant unsuitable for enrollment.
* Planning to relocate before the end of the study or planning to be away from the local area for an extended period during the scheduled study visits.
* Any condition that, in the opinion of the investigator, may interfere with the assessment of the study objectives.

Primary outcomes:
measure: Solicited AEs within 0-7 days after vaccination
timeFrame: Within 0-7 days after vaccination.
measure: Solicited systemic AEs within 0-7 days after vaccination
timeFrame: Within 0-7 days after vaccination.
Secondary outcomes:
measure: Unsolicited AEs within 0-28 days after vaccination
timeFrame: Within 0-28 days after vaccination.
measure: SAEs and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination
timeFrame: Within 0-6 months after vaccination.
measure: Laboratory testing clinically abnormalities on the 7th day after vaccination
timeFrame: On the 7th day after vaccination
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Emeritus Research
state: Victoria
Study officials:
affiliation: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
name: Lin Du
role: STUDY_CHAIR
References: